Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

EPOCH28

Financiado

Cerrado

Epigenetic Profiling of Chemotherapy Efficacy

The aim of this proposal is to showcase that chromatin regulators represent a novel class of biomarkers that can predict the response to individual drugs. The proof of concept will be established by validating our recent discovery... ver más

30/04/2017

INSTITUT CURIE FON...

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

INSTITUT CURIE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2017-04-30

ERC-PoC-2015: ERC Proof of Concept Grant

I+D

Cerrada hace 9 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

INSTITUT CURIE FONDATION

150.00K€ | Lider

ALBATROS MARINE TECHNOLOGIES

350.00K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

EPIGENETIC MARKER Evaluation of epigenetic biomarkers in prostate cancer patie... 75K€ Cerrado

EpiPredict Epigenetic regulation of endocrine therapy resistance in bre... 3M€ Cerrado

EPICAL Systematic Identification and Validation of Epigenetic Cance... 100K€ Cerrado

EPIPHARM Development of a ncRNA DNA Methylation Kit for Treatment Gui... 149K€ Cerrado

EVOEPIC Evolutionary mechanisms of epigenomic and chromosomal aberra... 1M€ Cerrado

ChromatinTargets Systematic in vivo analysis of chromatin associated targets... 1M€ Cerrado

Duración del proyecto: 18 meses Fecha Inicio: 2015-10-05
Fecha Fin: 2017-04-30

Líder del proyecto

INSTITUT CURIE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 150K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The aim of this proposal is to showcase that chromatin regulators represent a novel class of biomarkers that can predict the response to individual drugs. The proof of concept will be established by validating our recent discovery of a 28-gene signature of chromatin regulators that predicts the response of 26 out of 31 patient-derived xenograft breast cancer models to docetaxel. Notably, in patients treated with docetaxel, though all are subjected to toxic side effects, less than half of them clinically benefit, and no test exists to predict response. In the context of our funded ERC project, discoveries in our team underscored the key role of several chromatin regulators in establishing and maintaining chromatin landmarks, such as centromeres. In particular, our recent work demonstrated that mislocalization of the centromeric histone variant CenH3 gives cells an adaptive advantage to overcome DNA damage induced by camptothecin treatment and gamma irradiation. Further, preliminary evidence from our lab and others has highlighted a link between the expression level of chromatin regulators, including those involved in centromeres, and docetaxel sensitivity in a cellular context. Based on these promising studies, there are three aspects that we wish to develop as proof of concept for the use of chromatin regulators as novel predictive biomarkers for docetaxel treatment. First, we wish to further illustrate our chromatin regulators as a predictive signature for docetaxel treatment. For this, we will test samples from patients having received neoadjuvant docetaxel treatment alone. Secondly, we will test the applicability of our method in other cancers and drugs through an established collaboration with Roche to predict vemurafenib efficacy in melanoma. Thirdly, we will further evaluate the market need for predictive signatures for other commercial oncology drugs, and a potential spin-off that derives companion diagnostics for new drugs in clinical trails.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores